Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.

Name: Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
Author: Alobaidi, Sami

Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene. — المؤلف: Alobaidi, Sami — CEN case reports 20200318

المؤلف: Alobaidi, Sami
النشر: CEN case reports 20200318
الوصف: 139-143 p.
الموضوعات: Adult؛ Antibodies, Monoclonal, Humanized؛ Atypical Hemolytic Uremic Syndrome؛ Complement C3b Inactivator Proteins؛ Complement Factor H؛ Complement Inactivating Agents؛ Female؛ Humans